What is the market's earnings forecast for Outset Medical next quarter?

Did Outset Medical beat or miss consensus estimates last quarter?

What does Outset Medical do and what are its main business segments?

What is Outset Medical's latest dividend and current dividend yield?

What factors drove the changes in Outset Medical's revenue and profit?

What were the key takeaways from Outset Medical's earnings call?

What were the key takeaways from Outset Medical’s earnings call?

What is Outset Medical's gross profit margin?

- **Revenue miss due to timing**: Q3 revenue of $29.4M fell short of expectations due to large deals shifting to 2026. 2025 guidance revised to $115-$120M.
- **Gross margin milestone**: Non-GAAP gross margin reached 39.9%, up 350bps YoY, with a path to 50%.
- **Sales leadership change**: Head of Sales resignation may cause Q4 disruption; search underway for enterprise-focused leader.
- **Clinical validation**: 1M+ treatments show 94% reduction in cardiac events, reinforcing Tablo's value proposition.
- **Cash flow improvement**: Operating cash use down 94% YoY to $6M, with $182M cash on hand.

**【CEO Summary Section】**
 Outset Medical reported Q3 2025 revenue of $29.4 million, reflecting a 3% year-over-year increase. Key highlights include:
- **Shift in deal timing**: Several large enterprise deals, originally forecasted for Q3/Q4, are now expected to close in Q4 2025 and Q1 2026. This timing delay contributed to the revised 2025 revenue guidance of $115-$120 million (down from $122-$126 million).
- **Sales leadership transition**: The resignation of the Head of Sales, effective last week, may cause internal disruption in Q4. The company is conducting a search for a new leader with enterprise sales expertise.
- **Gross margin expansion**: Non-GAAP gross margin reached 39.9%, up 350 basis points year-over-year, driven by manufacturing efficiency improvements.
- **Clinical evidence growth**: Over 1 million Tablo treatments across 750 facilities demonstrated clinical benefits, including a 94% reduction in serious cardiac events at AdventHealth.

**【CFO Financial Commentary】**
- **Revenue breakdown**: Product revenue ($20.6M) and service revenue ($8.9M) both showed modest growth. Recurring revenue ($21.1M) was impacted by delayed orders from large acute care customers.
- **Gross margin details**: Product gross margin improved to 45.7% (from 43.2%), while service margin doubled to 24.8%. Full-year gross margin is expected to remain in the high 30% range.
- **Operating expenses**: Non-GAAP expenses declined 17% to $22.1M, reflecting $80M in cost savings implemented in 2024. Cash usage for the quarter was $6M, down from $100M in 2024.
- **Balance sheet**: $182M in cash provides sufficient liquidity through cash flow breakeven.

**【Q&A Key Highlights】**
- **Guidance rationale**: The $7M reduction in 2025 guidance reflects deal timing delays, sales leadership transition, and cautious forecasting around large customer ordering patterns.
- **Sales leadership criteria**: The company is seeking a leader with enterprise health system experience, capital equipment expertise, and a focus on deal predictability.
- **2026 outlook**: While no formal guidance provided, management emphasized the large addressable market and potential for differentiated growth rates as deal execution improves.
- **Acute care ordering patterns**: Q3 treatment orders lagged utilization by ~50%, but Q4 orders are aligning with usage data. Steps to synchronize ordering with utilization will be implemented in 2026.

Outset Medical, Inc. (OM) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue up 15% YoY to $31.4M, driven by console sales and 11% YoY recurring revenue growth. 
- **Gross Margin Expansion**: Non-GAAP GM 38.4% (up 110bps YoY), targeting 50% by end-2026. 
- **Enterprise Deal Momentum**: Signed agreement with largest health system for >100 facilities, with 900+ acute/subacute sites now using Tablo. 
- **Cash Efficiency**: Q2 cash use $18.5M (-46% YoY), on track for < $50M annual cash use. 
- **Home Market Expansion**: 15-20% of revenue with 90%+ patient retention, agreements with all 5 largest MDOs.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue of $31.4 million, up 15% YoY, driven by console sales and recurring revenue. Console sales grew sequentially and YoY, with recurring revenue at $22.5 million (11% YoY). 
- **Gross Margin Expansion**: Non-GAAP gross margin improved to 38.4%, up 110bps YoY, with product gross margin at 48.9%. Targeting 50% gross margin by end of 2026.
- **Market Penetration**: 900+ acute/subacute sites using Tablo; signed enterprise agreement with largest national health system for >100 facilities. 
- **Operational Efficiency**: Reduced cash use to $18.5 million (46% YoY decline), on track for < $50M annual cash use. 
- **Strategic Focus**: 3 priorities – grow console revenue, expand gross margin, drive profitability. Home market now 15-20% of revenue with 90%+ patient retention.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Product ($23.1M, +20% YoY) and Service ($8.3M, +2% YoY). Consumables up 17% YoY. 
- **Gross Margin Details**: Product GM 48.9% (vs 44.9% Q2 2024), Service GM 6.9% (vs 13.6% Q2 2024). 150bps under-absorption headwind expected for 2025. 
- **Expense Management**: Non-GAAP OpEx $25.4M (-19% YoY), Op loss $13.4M (-36% YoY). 
- **Cash Position**: $187.4M in cash, with < $50M annual cash use target. 
- **Guidance Update**: Raised 2025 revenue range to $122-126M (from $115-125M), with gross margin in high 30s% for full year.

**【Q&A Highlights】**
- **Pipeline Strength**: Q2 pipeline grew sequentially and YoY, with more deals in late stages. Enterprise deals drive higher console volumes. 
- **ASP Discipline**: Console ASP strength from TabloCart and PRO+ software adoption. 
- **Home Market Growth**: 15-20% of revenue, 90%+ patient retention. Signed agreements with all 5 largest MDOs. 
- **2026 Outlook**: CFO expects cash use to increase in 2026 due to production ramp, but remains confident in cash flow breakeven path. 
- **Tariff Update**: Tablo remains tariff-exempt under USMCA and chronic disability carve-out.

Outset Medical, Inc. (OM) Q2 2025 Earnings Call Transcript

- **Revenue Beat**: Q1 2025 revenue $29.8M (+6% YoY), driven by 23% QoQ console growth and 20% YoY recurring revenue. Console revenue ($7.1M) signals reignited growth.
- **Gross Margin Expansion**: 37.6% (up 650 bps YoY), with product margin at 48.4%. Excluding under-absorption, margin ~40%.
- **Operational Efficiency**: Operating loss $13.4M (lowest since IPO), $80M annualized cost savings. Cash position $192.3M supports 2025 breakeven.
- **Market Momentum**: Acute care adoption accelerates (100+ consoles in one IDN), subacute expansion begins. Home market gains new MDO contract.
- **Financial Health**: 2025 guidance: $115-125M revenue, < $50M cash use, path to profitability intact.

**【CEO Summary Section】**
- **Revenue Growth**: Q1 2025 revenue of $29.8 million, up 6% YoY, driven by 23% sequential growth in console revenue and 20% YoY increase in recurring revenue ($22.7 million). Console revenue reached $7.1 million, a key metric for reigniting growth.
- **Market Penetration**: Acute care providers continue to adopt Tablo for cost savings and clinical benefits. One regional IDN deployed its 100th console, while a large health system expanded from acute to subacute settings. Home market adoption grew with a new MDO contract.
- **Gross Margin Expansion**: Non-GAAP gross margin of 37.6% (up 650 bps YoY), with product margin at 48.4% and service margin at 10.3%. Excluding under-absorption of manufacturing overhead, gross margin would have been ~40%.
- **Operational Efficiency**: Non-GAAP operating loss of $13.4 million, lowest since IPO, with $80 million in annualized cost savings. Cash position of $192.3 million supports 2025 cash flow breakeven.
- **Sales Transformation**: Sales team tenure and pipeline growth improved, with forecast accuracy and deal progression metrics at record levels. Customer retention rates exceed 90%.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Product revenue ($21.3M) driven by console ($7.1M, +23% QoQ) and consumables ($14.2M). Service revenue ($8.5M) up 9% YoY. Recurring revenue ($22.7M) reflects 3 million cumulative treatments.
- **Gross Margin Details**: Product margin 48.4% (up 860 bps YoY), service margin 10.3% (up 230 bps YoY). Under-absorption of manufacturing overhead reduced gross margin by ~230 bps.
- **Expense Management**: Operating expenses down 30% YoY to $24.6 million. Non-GAAP net loss of $22.8 million, 22% lower YoY.
- **2025 Guidance**: Revenue $115-125 million (midpoint +12% YoY), gross margin in high 30s, OpEx ~$90 million, cash use < $50 million.

**【Q&A Highlights】**
- **Console Sales Momentum**: Sequential growth driven by volume, with ASP discipline. Acute and subacute sales processes similar, leveraging same team and value proposition (cost savings, clinical benefits).
- **Macroeconomic Resilience**: Hospitals prioritize Tablo due to tangible ROI (<12 months payback) and tariff-exempt supply chain. No impact from federal funding cuts observed.
- **Sales Team Performance**: Attrition at record low, with productivity gains in both capital and clinical sales. Field service CSAT >95%.
- **Guidance Conservatism**: Q1 strong execution, but cautious on remaining quarters. 2025 path to profitability intact, with $0.5 billion recurring revenue potential from current installed base.

Outset Medical (OM)-7 May 25-2025 Q1 Earnings call transcript

- **Revenue Resilience**: 2024 ended with $113.7 million revenue, 21% YoY recurring growth, and $210 million cash post-refinancing.
- **Gross Margin Leap**: 12% YoY expansion to 35.6%, targeting 50%+ with scale.
- **Pipeline Confidence**: 2025 console pipeline up 10% QoQ, 70% in late stages, signaling growth acceleration.
- **Cash Efficiency**: 2025 cash usage < $50 million, down 50% YoY, with $90 million OpEx target.
- **Clinical Impact**: 280% treatment growth at a hospital, reducing infections by 75%, proving Tablo's value.

**【CEO Summary Section】**
- **Revenue Performance**: Q4 2024 revenue of $29.5 million exceeded expectations, ending the year at $113.7 million. Recurring revenue grew 21% YoY to $83.9 million, with a run rate exceeding $100 million annually.
- **Gross Margin Expansion**: Non-GAAP gross margin expanded by nearly 12 percentage points in 2024, driven by higher treatment utilization and service leverage.
- **Balance Sheet Strengthening**: Secured $172.7 million in equity financing, reducing debt from $200 million to $100 million and extending maturity to 2030. Cash balance of $210 million provides runway to cash flow breakeven.
- **Market Momentum**: Installed base grew 10% YoY to nearly 6,000 consoles, with 4,500 in acute care settings. Treatment volume increased 280% at one hospital, reducing infections by 75%.

**【CFO Financial Commentary】**
- **Q4 Financials**: GAAP net loss of $19.3 million (-35% YoY), with non-GAAP gross margin of 37.6% (up 119 bps QoQ). Recurring revenue ($23.7 million) grew 13% QoQ and 17% YoY.
- **2025 Guidance**: Revenue expected between $115-125 million, with gross margin in the high 30% range. Operating expenses projected at $90 million, down 26% YoY. Cash usage expected under $50 million, less than half of 2024 levels.
- **Leverage Reduction**: Interest expense savings from debt refinancing and inventory management support cash flow improvement.

**【Q&A Key Takeaways】**
- **Console Growth**: 2025 pipeline up 10% QoQ, with 70% of top opportunities in late stages. Diversified pipeline includes new and expanding customers.
- **Treatment Strength**: Utilization growth and disciplined pricing drove recurring revenue beat, with no material stocking impact.
- **Cost Discipline**: R&D and SG&A cuts focused on non-core projects, preserving commercial execution strength. OpEx reduction enables 50%+ cash usage decline YoY.

Outset Medical, Inc. (OM) Q4 2024 Earnings Call Transcript

Outset Medical (OM)-6 Nov 24-2024 Q3 Earnings call transcript

Outset Medical (OM)-7 Aug 24-2024 Q2 Earnings call transcript

Outset Medical (OM)-8 May 24-2024 Q1 Earnings call transcript

- **Recurring Revenue Milestone**: 50% of Q4 revenue from consumables and services, up from 44% in 2022.
- **Gross Margin Expansion**: 26.7% in Q4 (960bps YoY), on track for 50%+ by 2027.
- **Home Market Breakthrough**: 25-patient home program milestone vs. <5 for incumbents, 95%+ retention rates.
- **TabloCart Catalyst**: Expected Q3 2024 return to market with prefiltration, targeting 1,400+ console placements in 2024.
- **Cash Efficiency**: $270M cash balance, targeting <50% annual cash burn reduction.

**【CEO Summary Section】**
- Q4 2023 revenue: $30.5 million (13% YoY growth), with 50% of total revenue from recurring streams (consumables and services). 
- Acute market: 700+ sites with 4,000+ consoles installed (20% penetration in top health systems), 80% of Q4 console sales included Tablo PRO+ ICU software.
- Home market: 1,300+ consoles deployed (+60% YoY), 25-patient home program milestone vs. <5 for incumbents, 95%+ retention rates.
- Gross margin expanded 960bps to 26.7% Q4, targeting 50%+ by 2027.
- Competitive moat: 95.4% field service satisfaction, 97% uptime, 25% cost-to-serve reduction.

**【CFO Financial Commentary】**
- Full year 2023 revenue: $130.4 million (+13% YoY), with 53% recurring revenue (vs. 44% 2022).
- Gross margin: 23.6% (vs. 16.1% 2022), driven by console cost-downs and service leverage.
- 2024 guidance: $145-153 million (+12-18%), non-GAAP gross margin 30-35%, OpEx $140-145 million (-13% YoY).
- Cash position: $270 million (including $66.5M term loan draw), targeting <50% annual cash burn reduction.

**【Q&A Key Highlights】**
- **TabloCart Update**: FDA interactive review ongoing, targeting Q3 2024 return to market with prefiltration.
- **Console Uptake**: 25% new customers in 2023, 75% expansions, 10,000+ nurses trained, 400+ clinicians educated.
- **Home Growth**: 1,300+ consoles, 25-patient program milestone, 3.5-year patient retention record.
- **Payer Trends**: 40% dialysis patients in Medicare Advantage, expected home push from payers post-2024.
- **Competitive Response**: 80% Q4 console sales included ICU-optimized Tablo PRO+, countering competitor claims.

OM

OM fundamentals

Earnings Call

You can ask Aime